Open an account

Oruka Therapeutics

ORKA · NASDAQ

$79.09+$4.61 (+6.19%)TodayMarket closed ·
Prev close $74.48

About ORKA

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. The company is headquartered in Menlo Park, California and currently employs 68 full-time employees. The company went IPO on 2000-07-21. The firm is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).

Employees
68
Headquarters
Menlo Park, California
Listed
Jul 21, 2000
Sector
Health Care
Industry
Biotechnology
Website
orukatx.com

ORKA key statistics

Market cap
5.24B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.03M
Volume
787.75K
Open price
$74.42
High today
$79.90
Low today
$74.42
52 Week high
$115.52
52 Week low
$25.11

Oruka Therapeutics (ORKA) at a glance

Oruka Therapeutics (ORKA) last traded at $79.09, with a market cap of 5.24B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $74.42 and $79.90. The current price is 6.3% above the day's low and 1.0% below its high.

Volume so far is 787.75K shares, below the average of 1.03M shares a day.

Over the past year Oruka Therapeutics has ranged from $25.11 to $115.52, and now sits 60% of the way up that range.

Oruka Therapeutics met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.55 per share against an estimate of -$0.5257.

The average analyst price target is $156.22, 97.5% above the current price, from 10 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 10 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 15 analystsAvg $156.22
Low
$118.17
Now
$79.09
High
$210.00

ORKA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 18.5% on average.

  1. Q3 FY24: reported -$1.46 per share against an estimate of -$0.4099
  2. Q4 FY24: reported -$0.49 per share against an estimate of -$0.6955
  3. Q1 FY25: reported -$0.40 per share against an estimate of -$0.5161
  4. Q2 FY25: reported -$0.46 per share against an estimate of -$0.4998
  5. Q3 FY25: reported -$0.55 per share against an estimate of -$0.5931
  6. Q4 FY25: reported -$0.45 per share against an estimate of -$0.64
  7. Q1 FY26: reported -$0.48 per share against an estimate of -$0.5602
  8. Q2 FY26: reported -$0.55 per share against an estimate of -$0.5257

ORKA news

  • 10 Health Care Stocks Whale Activity In Today’s Session

  • Vandana Singh

    Oruka Therapeutics Says Psoriasis Drug Shows Deepening Efficacy

  • Tanya Rawat

    Oruka Therapeutics Shares Drop After Hours After Fairmount Unloads 3.55 Million Shares

  • Press releaseGlobe Newswire

    Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation

  • Press releaseGlobe Newswire

    Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

  • Press releasePRNewswire

    Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

  • Vandana Singh

    Oruka Therapeutics Stock Explodes As Psoriasis Data Shows 'Highly Compelling' Skin Clearance

  • Press releaseGlobe Newswire

    Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis

Similar companies

Companies in the same industry as Oruka Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.